Valneva Announces New IXIARO® Supply Contract with the U.S. Government Worth a Minimum of $32.8 Million
Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced the signing of a new $32.8 million contract with the United States (U.S.) Department of Defense (DoD) for ...
GlobalData on MSN12d
SK bioscience and Sanofi’s GBP410 vaccine enters global Phase III trials
SK bioscience and Sanofi have announced plans for global Phase III studies, which will assess the safety and immunogenicity ...
ABC Health on MSN8d
Inside the race to create a Japanese encephalitis vaccine for pigs
The Australian pig industry hopes work to develop a vaccine to protect its animals against Japanese encephalitis virus can be ...
Medical Xpress23d
T cells' capability to fully prevent acute viral infections opens new avenues for vaccine development
As the Japanese encephalitis vaccine was constructed using the backbone of the yellow fever vaccine, inoculation with either one of the vaccines generates T cells that are effective against both ...
STAT3d
When your child can’t walk and it could be polio
When her 5-year-old son’s legs stopped working and a doctor said the word “polio,” this writer felt a terror she never ...
Valneva Is A 'Buy' As A First-Mover In Chikungunya
Valneva’s growth potential lies in Ixchiq, but risks remain. Find out why VALN stock is still a Buy with a good long-term ...
Positive Outlook for Valneva: Favorable Vaccine Trials and Expanding Market Potential
H.C. Wainwright analyst Edward White reiterated a Buy rating on Valneva (VALN – Research Report) today and set a price target of $18.00.Invest ...